Geriatric Factors and Quality of Life Impact Survival in Metastatic Pancreatic Cancer
• A recent study revealed that baseline geriatric assessment (GA) vulnerabilities and quality of life (QOL) scores correlate with overall survival (OS) in metastatic pancreatic cancer patients.
• The ECOG-ACRIN EA2186 (GIANT) trial identified Instrumental Activities of Daily Living (IADL), nutrition, depression, and FACT-HEP as significant factors affecting OS.
• The study suggests that managing geriatric vulnerabilities and QOL could improve outcomes and aid in selecting patients who benefit from chemotherapy.
• Patients receiving at least four weeks of treatment showed a median overall survival of 8.0 months, highlighting the importance of treatment duration.
Landmark Cardiology Advancements: Novel Therapies and Key Trial Results in 2024
• Tirzepatide shows promise in reducing heart failure hospitalization or cardiovascular death by 38% in obese patients with HFpEF.
• Finerenone demonstrates a 16% reduction in cardiovascular death and heart failure hospitalizations in patients with HFmrEF/HFpEF.
• Semaglutide reduces major kidney disease events by 24% and cardiovascular death by 29% in patients with type 2 diabetes and chronic kidney disease.
• FDA approves semaglutide for cardiovascular risk reduction in adults with cardiovascular disease and obesity, marking a milestone for weight loss medications.
FDA Approves Journavx, a Novel Non-Opioid Painkiller, Offering New Hope for Acute Pain Management
• The FDA has approved Journavx (suzetrigine), a first-in-class non-opioid analgesic, for treating moderate to severe acute pain in adults, offering a safer alternative to opioids.
• Journavx works by selectively blocking pain signals in the peripheral nervous system, reducing pain without the addictive potential and severe side effects associated with opioids.
• Clinical trials demonstrated Journavx's effectiveness in reducing pain after surgeries, with a safety profile comparable to placebo, though it didn't outperform opioid-acetaminophen combinations.
• Priced at $15.50 per pill, Journavx faces challenges in accessibility due to its higher cost compared to generic opioids, but it represents a significant step in combating the opioid crisis.
Aficamten Shows Potential to Help oHCM Patients Avoid Septal Reduction Therapy
• A subgroup analysis from the FOREST-HCM trial revealed that aficamten could reduce the need for septal reduction therapy (SRT) in obstructive hypertrophic cardiomyopathy (oHCM) patients.
• After 24 weeks of aficamten treatment, approximately 70% of SRT-eligible patients were no longer considered eligible for the procedure.
• The study also demonstrated improvements in NYHA functional class, with a significant proportion of SRT-eligible patients experiencing at least a one-class improvement.
• Aficamten demonstrated greater improvements in SRT-eligible patients relative to those in the remaining cohort (21.7 [SD, 19.3] vs 13.5 [SD, 13.9]; P = .003).
RenovoRx Advances TIGeR-PaC Trial for Pancreatic Cancer with Novel TAMP Therapy
• RenovoRx's TIGeR-PaC Phase III trial evaluates TAMP therapy for locally advanced pancreatic cancer, aiming to improve survival and reduce side effects.
• SCRI Oncology Partners has initiated patient enrollment, expanding the trial's reach across a network of over 250 locations in the U.S.
• Pharmacokinetic data presented at ASCO GI 2025 supports TAMP's potential to enhance local drug potency while minimizing systemic exposure to gemcitabine.
• RenovoRx anticipates completing patient enrollment and the second interim analysis for the TIGeR-PaC trial by the first half of 2025.
NIH Launches CARE for Health Network to Enhance Primary Care Research
• The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care.
• Three inaugural research hubs have been selected at Oregon Health and Science University (OHSU), University of Wisconsin-Madison (UW), and West Virginia University (WVU).
• The network will focus on improving access to clinical research for underserved communities and those underrepresented in research.
• Initial studies will address chronic back pain, polysubstance abuse, and gout, engaging rural communities through existing NIH-funded trials.
ZKR Orthopedics Initiates FDA Trial for Patella LIFT Procedure in Patellofemoral Arthritis
• ZKR Orthopedics has commenced its FDA PELICAN trial with the first U.S. patella LIFT procedure for patellofemoral arthritis.
• The minimally invasive Patella LIFT aims to alleviate pain by unloading the patella, offering a less complex alternative to traditional surgeries.
• The PELICAN study will compare the Patella LIFT Implant to tibial tubercle osteotomy, assessing patient-reported outcomes and safety.
• The trial, involving multiple sites in the U.S. and Europe, follows promising results from a European pilot study showing improved function.
Gene Therapy Shows Promise in Restoring Vision for LCA1 Patients
• A Phase 1/2 clinical trial of ATSN-101 gene therapy demonstrates significant vision improvement in patients with Leber congenital amaurosis type 1 (LCA1).
• Some patients experienced up to a 10,000-fold increase in light sensitivity, enabling them to see in dimly lit environments.
• The gene therapy, developed by Atsena Therapeutics, showed a favorable safety profile with mostly mild, surgery-related side effects.
• These findings support a future Phase 3 trial to further evaluate the efficacy and safety of ATSN-101 for LCA1, a rare inherited blindness.
Aficamten Shows Long-Term Safety and Cardiac Benefits in HCM Patients
• Integrated safety analysis of aficamten across three clinical trials reinforces its robust safety profile, with adverse events similar to placebo.
• FOREST-HCM analysis demonstrates successful withdrawal of standard of care medications in obstructive HCM patients treated with aficamten.
• SEQUOIA-HCM data shows aficamten improves cardiac remodeling, structure, function, and biomarkers, suggesting potential disease modification.
• Aficamten significantly improves symptom burden and quality of life in patients with obstructive HCM, as measured by KCCQ-OSS and SAQ-SS.
Gene Therapy for Hemophilia A Shows Sustained Clotting Factor Expression and Reduced Bleeding
• A novel gene therapy, SPK-8011, demonstrates stable coagulation factor VIII expression in hemophilia A patients, offering a potential long-term treatment option.
• The phase 1/2 trial showed a 91.5% reduction in bleeding episodes among participants, with most maintaining FVIII expression for the duration of the study.
• The therapy involves a recombinant AAV vector engineered to produce FVIII in liver cells, providing a one-time, disease-altering approach.
• While most participants responded well, two experienced a loss of expression due to an immune response, highlighting the need for further research.
© Copyright 2025. All Rights Reserved by MedPath